Universität zu Köln

van Rijssen, Thomas J., van Dijk, Elon H. C., Scholz, Paula, Breukink, Myrte B., Dijkman, Greet, Peters, Petrus J. H., Tsonaka, Roula, MacLaren, Robert E., Downes, Susan M., Fauser, Sascha, Boon, Camiel J. F. and Hoyng, Carel B. (2020). Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous Chorioretinopathy: The REPLACE Trial. Am. J. Ophthalmol., 216. S. 80 - 90. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-1891

Full text not available from this repository.

Abstract

PURPOSE: To assess whether chronic central serous chorioretinopathy (cCSC) patients without a complete resolution of subretinal fluid (SRF) after either half-dose photodynamic therapy (PDT) or high-density subthreshold micropulse laser (HSML) treatment may benefit from crossover treatment. DESIGN: Multicenter prospective interventional case series. METHODS: cCSC patients with persistent SRF at the final visit of the PLACE trial were included. Patients received crossover treatment with either half-dose PDT or HSML. RESULTS: Thirty-two patients received PDT and 10 patients received HSML. At the first evaluation visit (6-8 weeks after treatment), 81% of patients in the PDT group had complete resolution of SRF, while none of the HSML-treated patients had complete resolution of SRF. At final visit (1 year after baseline), 78% (P = .030) and 67% (P = .109) of the patients, respectively, had a complete resolution of SRF. The mean retinal sensitivity in the PDT group increased from 21.7 dB (standard error [SE]: 0.9) to 23.4 dB (SE: 0.8) at evaluation visit 1 (P = .003), to 24.7dB (SE: 0.8) at final visit (P < .001), while there were no significant changes in the HSML group (23.7 dB [SE: 1.6] at baseline, 23.8 dB [SE: 1.4] at evaluation 1, and 23.3 dB [SE: 1.4] at final visit). The mean visual acuity and mean visual quality-of-life questionnaire score did not change significantly in both groups. CONCLUSIONS: Crossover to half-dose PDT after previous unsuccessful HSML treatment for cCSC may lead to improved anatomic and functional endpoints, while crossover to HSML after half-dose PDT does not seem to significantly affect these endpoints. (C) 2020 The Authors. Published by Elsevier Inc.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code van Rijssen, Thomas J. UNSPECIFIED UNSPECIFIED UNSPECIFIED van Dijk, Elon H. C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Scholz, Paula UNSPECIFIED UNSPECIFIED UNSPECIFIED Breukink, Myrte B. UNSPECIFIED UNSPECIFIED UNSPECIFIED Dijkman, Greet UNSPECIFIED UNSPECIFIED UNSPECIFIED Peters, Petrus J. H. UNSPECIFIED UNSPECIFIED UNSPECIFIED Tsonaka, Roula UNSPECIFIED UNSPECIFIED UNSPECIFIED MacLaren, Robert E. UNSPECIFIED UNSPECIFIED UNSPECIFIED Downes, Susan M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Fauser, Sascha UNSPECIFIED UNSPECIFIED UNSPECIFIED Boon, Camiel J. F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Hoyng, Carel B. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-324337
DOI:	10.1016/j.ajo.2020.04.007
Journal or Publication Title:	Am. J. Ophthalmol.
Volume:	216
Page Range:	S. 80 - 90
Date:	2020
Publisher:	ELSEVIER SCIENCE INC
Place of Publication:	NEW YORK
ISSN:	1879-1891
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CLINICAL CHARACTERISTICS; DIODE-LASER; VERTEPORFIN; PHOTOCOAGULATION Multiple languages Ophthalmology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/32433